Caglar Sena Ebru, Karakoc Yunus, Tanoglu Alpaslan, Demirtunc Refik, Tanrikulu Seher, Kilickaya Hande, Ercan Muhterem
Hamidiye Faculty of Medicine, Department of Physiology, University of Health Sciences, Istanbul, Türkiye.
Hamidiye Faculty of Medicine, Department of Biophysics, University of Health Sciences, Istanbul, Türkiye.
Thyroid Res. 2025 Mar 20;18(1):11. doi: 10.1186/s13044-025-00227-w.
Hyperthyroidism's impact on cardiovascular, hematopoietic systems and metabolism might lead to hemorheological changes. This study aimed to investigate the changes in hemorheological properties via erythrocyte deformability and aggregation, whole blood viscosity (WBV) and plasma viscosity (PV) in hyperthyroid patients. The effect of anti-thyroid treatment on hemorheology was also studied. MATERIAL METHODS: Thirty-six patients with overt hyperthyroidism, 19 patients with subclinical hyperthyroidism and 66 controls were included in the study. Hematocrit, erythrocyte deformability and aggregation, plasma and whole blood viscosity values were measured before treatment. Hemorheological parameters of the patients were compared with the control. Before and after treatment results of overt hyperthyroidism were analyzed. Methimazole was given as anti-thyroid treatment. Deformability and aggregation measurements were conducted using a laser ektacytometer (LORRCA) while viscosity measurements were performed with a cone-plate viscometer (Brookfield DV-III).
The maximum elongation index (EImax) decreased significantly from 0.664 (0.01) pre-treatment to 0.657 (0.01) post-treatment (p = 0.04). The aggregation index was significantly higher in both the subclinical hyperthyroidism group [68.05 (7.66), p = 0.001] and the overt hyperthyroidism group [66.78 (8.815), p = 0.001] compared to the control group. Additionally, the aggregation half-time was significantly shorter in the subclinical hyperthyroidism group [1.9 (1.21-2.27), p = 0.001] and the overt hyperthyroidism group [1.91 (1.43-2.46), p = 0.001] relative to the control group.
The hemorheological status of patients was influenced by excessive thyroid hormones in both subclinical and overt hyperthyroidism groups. Additionally, anti-thyroid therapy with methimazole may play a role in the observed decrease in the maximum elongation index following treatment.
甲状腺功能亢进对心血管、造血系统及代谢的影响可能导致血液流变学改变。本研究旨在通过检测甲状腺功能亢进患者的红细胞变形性和聚集性、全血粘度（WBV）及血浆粘度（PV）来研究血液流变学特性的变化。同时还研究了抗甲状腺治疗对血液流变学的影响。
本研究纳入了36例显性甲状腺功能亢进患者、19例亚临床甲状腺功能亢进患者及66例对照者。在治疗前测量血细胞比容、红细胞变形性和聚集性、血浆及全血粘度值。将患者的血液流变学参数与对照组进行比较。分析显性甲状腺功能亢进患者治疗前后的结果。给予甲巯咪唑进行抗甲状腺治疗。使用激光衍射血细胞分析仪（LORRCA）进行变形性和聚集性测量，而粘度测量则使用锥板粘度计（Brookfield DV-III）进行。
最大伸长指数（EImax）从治疗前的0.664（0.01）显著降至治疗后的0.657（0.01）（p = 0.04）。与对照组相比，亚临床甲状腺功能亢进组[68.05（7.66），p = 0.001]和显性甲状腺功能亢进组[66.78（8.815），p = 0.001]的聚集指数均显著更高。此外，与对照组相比，亚临床甲状腺功能亢进组[1.9（1.21 - 2.27），p = 0.001]和显性甲状腺功能亢进组[1.91（1.43 - 2.46），p = 0.001]的聚集半衰期显著更短。
亚临床和显性甲状腺功能亢进组患者的血液流变学状态均受到甲状腺激素过多的影响。此外，甲巯咪唑抗甲状腺治疗可能在治疗后观察到的最大伸长指数下降中发挥作用。
